rethinkTHC Search
Menu
Study breakdown

Most cannabis driving research uses products far weaker than what people actually buy, creating a major evidence gap

Systematic ReviewModerate evidence
The takeaway

Almost all cannabis driving research has used ~6% THC products, while today's market sells flower exceeding 20% THC and concentrates above 60%, creating a large gap between research and reality.

Driving safety researchers, policymakers, forensic scientists, anyone interested in cannabis impairment evidence

Research uses ~6% THC while commercial products exceed 20-60% THC

What the researchers found

Nearly all driving impairment studies used inhaled cannabis at approximately 6% THC, far below the 20%+ THC flower and 60%+ THC concentrates now sold commercially. The dose-response relationship at higher potencies and the impairment timeline for different administration routes (edibles, vaping) remain largely unstudied.

Why it matters

If driving research only tests products a fraction of the potency people actually use, the real-world impairment from modern cannabis products may be significantly underestimated, leaving a dangerous gap in safety knowledge.

The numbers in context

Research typically uses ~6% THC; commercial flower can exceed 20% THC; extracts can contain 60%+ THC; crash risk increases approximately 2-fold after smoking marijuana

How the study worked

Systematic review following PRISMA guidelines of PubMed literature and grey literature (congressional reports, committee reports, roadside surveys) on cannabis impairment and driving performance modeling.

What this study cannot tell us

Federal restrictions on cannabis research have limited access to products matching commercial potency. Many studies use vaporized rather than smoked cannabis. Naturalistic driving studies introduce uncontrollable variables.

How to read the evidence

Systematic review identifying critical gaps between research conditions and real-world cannabis products

When this study was published

Published in 2021. Cannabis potency continues to increase in commercial markets.

The bigger picture

The mismatch between research cannabis and commercial cannabis undermines the evidence base for both driving laws and public safety messaging about cannabis impairment.

Questions still open

  • Does higher potency cannabis produce proportionally more driving impairment? How does the extended impairment timeline from edibles compare to inhalation? Can existing impairment models be recalibrated for modern-potency products?

Common questions

How does cannabis affect driving?
Research shows crash risk approximately doubles after smoking cannabis. However, almost all studies used products around 6% THC, far weaker than the 20%+ THC products people actually buy.
Why is there a gap between cannabis research and reality?
Federal restrictions have limited researchers to low-potency cannabis. Commercial products now contain 3-10 times more THC than research products, meaning real-world impairment may be significantly greater than studies suggest.

Read the original research

Mechanisms of cannabis impairment: Implications for modeling driving performance.

Forensic science international, 328, 110902

Citation

Burt, Thomas S; Brown, Timothy L; Milavetz, Gary; McGehee, Daniel V. (2021). Mechanisms of cannabis impairment: Implications for modeling driving performance.. Forensic science international, 328, 110902. https://doi.org/10.1016/j.forsciint.2021.110902